Ocrelizumab (Ocrevus®) is an intravenously administered, humanized anti-CD20
monoclonal antibody approved for the treatment of adults with relapsing forms of multiple …

Purpose of review FDA-approved B cell-targeted therapy has expanded to a multitude of
autoimmune diseases ranging from organ specific diseases, like pemphigus and multiple …

Background: The Association of British Neurologists (ABN) 2015 guidelines suggested
classifying multiple sclerosis therapies according to their average relapse reduction. We …

Objective To compare the efficacy and compliance of up-to-date disease modifying
therapies (DMTs) in patients with remitting-relapsing MS (RRMS). Methods We searched …

Aim: To compare the efficacy of ofatumumab to other disease-modifying therapies (DMTs)
for relapsing multiple sclerosis (RMS). Materials & methods: A network meta-analysis was …

Current therapeutic landscape in multiple sclerosis: an evol... : Current Opinion in
Neurology Current therapeutic landscape in multiple sclerosis: an evolving treatment …

Abstract Background Since 2010, 27 mixed-treatment comparisons (MTCs) of disease-
modifying therapies (DMTs) for multiple sclerosis have been published. However, there has …

Background Currently, 19 disease-modifying therapies (DMTs) have been approved for the
treatment of patients with relapsing forms of multiple sclerosis (RMS). Objective The …

Cumulative evidence along several lines indicates that B cells play an important role in the
pathological course of multiple sclerosis (MS), neuromyelitisoptica spectrum disorders …

Aim: To assess the relative efficacy of disease-modifying therapies (DMTs) for relapsing
multiple sclerosis (RMS) including newer therapies (ozanimod, ponesimod, ublituximab) …